Form 4: Acurx Pharmaceuticals Director Joseph Scodari Acquires Stock Options

Director Joseph C. Scodari acquired 12,000 stock options in Acurx Pharmaceuticals on June 17, 2024, related to his board service.

Summary

• Joseph C. Scodari, a director of Acurx Pharmaceuticals, acquired 12,000 stock options on June 17, 2024.
• The options have an exercise price of $2.38.
• These options were granted as part of the Issuer's Director Compensation Policy.
• The shares subject to the options will vest on June 17, 2025.
• The options expire on June 17, 2034.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock option grants to a director, which is a common practice.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Stock option grants to directors are a common practice in the pharmaceutical industry as part of compensation packages to align their interests with those of shareholders.

Comparison to Industry Standards

• Director compensation packages, including stock options, vary widely across the pharmaceutical industry depending on company size, stage of development, and performance.
• Comparing Acurx's director compensation to that of similar-sized biotech companies would provide a better benchmark.
• Companies like Spero Therapeutics or Iterum Therapeutics could be considered for comparison, although their specific compensation structures would need to be analyzed.

Stakeholder Impact

• The granting of stock options aligns the director's interests with those of the shareholders, potentially encouraging decisions that increase shareholder value.

Key Dates